NCT00881166 2024-08-02
SGI-0470-02
Astex Pharmaceuticals, Inc.
Phase 1 Completed
Clinical Trials
3 trialsNCT00894894 2024-08-02
Safety Study to Determine the Maximum Tolerated Dose, Pharmacokinetics and Pharmacodynamics of Oral MP470, a Multitargeted Tyrosine Kinase Inhibitor, in Patients With Solid Malignancies
Astex Pharmaceuticals, Inc.
Phase 1 Completed
NCT01357395 2024-08-02
ESCAPE
Astex Pharmaceuticals, Inc.
Phase 2 Completed